Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
Federica TomaoGiusi SantangeloLucia MusacchioViolante Di DonatoMargherita FischettiAntonella GiancottiGiorgia PerniolaMaria Cristina PetrellaMarco MontiInnocenza PalaiaLudovico MuziiPierluigi Benedetti PaniciPublished in: Journal of cellular physiology (2020)
Patients with metastatic and recurrent cervical cancer (CC) have a poor prognosis with limited palliative treatment options. Increasing understanding of the cellular aberrations inherent to cancer cells has allowed the development of therapies to target biological pathways, an important step toward the individualization of cancer therapy. The poly (ADP-ribose) polymerase (PARP) family of enzymes is important in several DNA repair pathways. Drugs that inhibit these PARP enzymes have been investigated in many types of cancer and their application in the treatment of gynecologic malignancies has rapidly evolved. Although the majority of data for PARPi in gynecologic malignancies has been specifically regarding ovarian cancer, their role in the treatment of uterine and CC is currently being investigated. This review will examine PARP inhibitors in CC, summarizes the critical clinical trials of PARP inhibitors that have been completed, provides an overview of the on-going trials, presents the confirmed conclusions and notes the issues that need to be addressed in future studies.
Keyphrases
- dna repair
- dna damage
- poor prognosis
- cancer therapy
- clinical trial
- dna damage response
- long non coding rna
- palliative care
- drug delivery
- atomic force microscopy
- combination therapy
- randomized controlled trial
- dna methylation
- squamous cell carcinoma
- gene expression
- machine learning
- copy number
- mass spectrometry
- structural basis
- open label
- data analysis
- study protocol